Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry

Biocon Academy conducts 8th Graduation Day

Five batches across four programs of Biocon Academy participated in the graduation ceremony

Biocon names Peter Bains as Group CEO

Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect

Kiran Mazumdar-Shaw appointed as member of the Court of Regents at the Royal College of Surgeons of Edinburgh

The RCSed's Court of Regents comprises a group of distinguished and accomplished individuals in their field

Biocon approves NCD issue

The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.

Biocon awarded Silver Medal by EcoVadis for sustainability accomplishments

For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)

Biocon Q3 FY23 revenue up 36%

The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses

Biocon initiates clinical study of Itolizumab for ulcerative colitis in India

This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

Biocon ranks No. 8 in ‘Global Top Employers’ by Science magazine

The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’